New Diabetes Drug Reduces Heart Attack and Stroke Risk

Great news for people with diabetes and kidney disease! A newly FDA-approved drug called Sotagliflozin has been proven to significantly lower the risk of heart attacks and strokes.

What is Sotagliflozin?

Sotagliflozin is a medication designed to treat type 2 diabetes and kidney disease. What makes it different from other diabetes drugs is its ability to target two types of proteins at once: SGLT1 and SGLT2. This unique combination provides extra benefits for heart and blood vessel health.

Promising Research Results

An international clinical trial led by researchers from Mount Sinai found that Sotagliflozin can reduce the risk of heart attacks and strokes by up to 23% compared to patients who did not take the drug.

The study, called the “SCORED Trial,” involved 10,584 patients with chronic kidney disease, type 2 diabetes, and other cardiovascular risk factors. They were divided into two groups: one took Sotagliflozin, while the other received a placebo. The results? Patients who took Sotagliflozin experienced a significant decrease in heart attacks, strokes, and deaths related to cardiovascular disease.

Fast-Acting Benefits

One interesting finding from this research is that the benefits of Sotagliflozin started appearing within just three months of use. Usually, chronic disease medications take longer to show effects.

According to Dr. Deepak L. Bhatt from Mount Sinai, these results suggest that Sotagliflozin could be a new option for doctors to help reduce heart attack and stroke risks, especially for patients with heart or kidney disease.

New Hope for Patients

With this new data, Sotagliflozin is expected to become widely used worldwide to help patients with type 2 diabetes and kidney disease who are at high risk of cardiovascular problems.

This study was funded by Lexicon Pharmaceuticals, in collaboration with the Icahn School of Medicine at Mount Sinai, supporting Dr. Bhatt and his research team.

For people with type 2 diabetes and kidney disease who have a high risk of heart attacks or strokes, Sotagliflozin could be a new, more effective way to protect heart health. Always consult with a doctor before trying any new medication.

Source The Lancet